• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Zymeworks Inc. - Common Stock (NQ:ZYME)

    23.89 -2.71 (-10.19%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,454,525
    Open 26.21
    Bid (Size) 23.91 (100)
    Ask (Size) 24.02 (100)
    Prev. Close 26.60
    Today's Range 23.39 - 26.21
    52wk Range 10.93 - 29.75
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Zymeworks Q1 Earnings Call Highlights ↗
    Zymeworks (NASDAQ:ZYME) reported a wider first-quarter loss as revenue declined from year-earlier milestone payments, while management highlighted regulatory catalysts for zanidatamab, progress across... 
    Via MarketBeat
    Topics Earnings
    Zymeworks (NASDAQ:ZYME) Misses Q1 Estimates But August PDUFA Date for Zanidatamab Offers Key Regulatory Catalyst ↗
    Via Chartmill

    Performance

    YTD
    -10.3%
    -10.3%
    1 Month
    -9.2%
    -9.2%
    3 Month
    +6.1%
    +6.1%
    6 Month
    +32.4%
    +32.4%
    1 Year
    +98.8%
    +98.8%

    More News

    Read More
    News headline image
    Zymeworks (ZYME) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Inc (NASDAQ:ZYME) Posts Wider Q4 Loss Despite Strategic Progress and Royalty Deal ↗
    Via Chartmill
    News headline image
    Capricorn Fund Makes a Huge Bet on Nerve Repair With 687,000 Share Axogen (AXGN) Investment Worth $22.4 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks Appoints Kristin Stafford as Chief Financial Officer
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks Announces Participation in Upcoming Investor Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗
    Via The Motley Fool
    News headline image
    Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
    From Zymeworks Inc.
    Via GlobeNewswire
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
    Via Benzinga
    Topics Stocks
    News headline image
    Zymeworks (ZYME) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
    From Royalty Pharma plc
    Via GlobeNewswire
    News headline image
    Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks Announces Participation in Upcoming Investor Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    News headline image
    Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
    From Zymeworks Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Zymeworks Inc. - Common Stock publicly traded?
    Yes, Zymeworks Inc. - Common Stock is publicly traded.
    What exchange does Zymeworks Inc. - Common Stock trade on?
    Zymeworks Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Zymeworks Inc. - Common Stock?
    The ticker symbol for Zymeworks Inc. - Common Stock is ZYME on the Nasdaq Stock Market
    What is the current price of Zymeworks Inc. - Common Stock?
    The current price of Zymeworks Inc. - Common Stock is 23.89
    When was Zymeworks Inc. - Common Stock last traded?
    The last trade of Zymeworks Inc. - Common Stock was at 05/08/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.